✨ Onyx Summary Legend Biotech announced it will present eight abstracts on CARVYKTI® and new first-in-human data on Lucar-G39D at the 2025 ASH Annual Meeting, showcasing advances in CAR-T and allogeneic cell therapies. The presentations highlight CARVYKTI’s sustained efficacy and expanding real-world use in multiple myeloma, alongside early progress in
SAN DIEGO, Nov. 03, 2025 – Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time
✨ Onyx Summary Foghorn Therapeutics announced management participation in three upcoming investor events—the Guggenheim Healthcare Innovation, Stifel 2025 Healthcare, and Jefferies 2025 London Healthcare Conferences—featuring presentations by CEO Adrian Gottschalk. The company will use these forums to engage investors and highlight progress of its Gene Traffic Control® platform and
✨ Onyx Summary Belite Bio (NASDAQ: BLTE) said the UK MHRA will accept a Conditional Marketing Authorization application for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results, with final topline data expected in Q4 2025 for subsequent full MAA submission. The pivotal DRAGON trial enrolled 104 adolescent patients
✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) announced its senior leadership will participate in the Truist Securities BioPharma Symposium on November 6, 2025, and the UBS Global Healthcare Conference on November 11, 2025, where it will host a fireside chat. The company continues to engage the investment community as it
✨ Onyx Summary Lexicon Pharmaceuticals (Nasdaq: LXRX) announced it will release its third-quarter 2025 financial results before market open on November 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET to discuss results and provide a business update. THE WOODLANDS, TEXAS, OCT. 30, 2025 — Lexicon
✨ Onyx Summary Saama launched its Tables, Listings, and Figures (TLF) Analyzer, an AI-driven solution that automates interpretation and summarization of complex clinical data to accelerate clinical study report (CSR) authoring. Integrating multimodal GenAI capable of converting graphical outputs—such as Kaplan–Meier and forest plots—into context-rich text, the tool
✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced advancements across its targeted protein degrader portfolio, including progress on its selective ARID1B, CBP, and EP300 degrader programs, with preclinical data showing promise in multiple solid and hematologic cancers and an IND filing for its CBP degrader planned for 2026. The updates underscore
✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced its participation in upcoming investor events, including one-on-one meetings at the UBS Global Healthcare Conference on November 12 and a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20. Live and archived webcasts of the
✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) announced positive interim results from the Phase 2 portion of its registrational KYSA-6 trial showing that a single dose of KYV-101, a CD19 CAR T-cell therapy, achieved rapid, durable, and clinically meaningful improvements in all treated patients with generalized myasthenia gravis. The therapy demonstrated
✨ Onyx Summary Belite Bio (Nasdaq: BLTE) announced that its executive management team will present a corporate update at the Deutsche Bank ADR Virtual Investor Conference on November 4, 2025, at 10:30 a.m. ET. SAN DIEGO, Oct. 29, 2025 – Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a
✨ Onyx Summary Legend Biotech (NASDAQ: LEGN) announced it will host a conference call on November 12, 2025, at 8:00 a.m. ET to discuss its third-quarter financial results and business performance. The company, co-developer of CARVYKTI® for multiple myeloma, continues to expand its leadership in cell therapy and build
✨ Onyx Summary Recursion (Nasdaq: RXRX) announced it will report third-quarter 2025 financial results and provide business updates on November 5, 2025, before market open, followed by a live-streamed “(L)earnings Call” at 8:00 a.m. ET across its social media channels. The company continues to leverage its Recursion OS
✨ Onyx Summary Verily announced a collaboration with NVIDIA to integrate NVIDIA’s AI technology stack—including NeMo, Parabricks, and CUDA-X—into its Pre platform, significantly accelerating genomic and AI model analyses across healthcare research environments such as the NIH’s All of Us Researcher Workbench. The partnership enhances Verily’s
✨ Onyx Summary Geron Corporation (Nasdaq: GERN) announced it will release its third-quarter 2025 financial results and business highlights before market open on November 5, 2025, followed by a conference call and webcast at 8:00 a.m. ET. The live and archived webcast will be accessible on Geron’s investor
✨ Onyx Summary Guardant Health (Nasdaq: GH) and Zephyr AI announced a strategic partnership to combine Guardant’s multimodal molecular data with Zephyr’s AI and machine learning technologies to advance cancer biomarker discovery, drug development, and treatment response prediction. The collaboration, part of Guardant’s Infinity AI platform, underscores a
